Date post: | 12-Jan-2016 |
Category: |
Documents |
Upload: | emily-shaw |
View: | 212 times |
Download: | 0 times |
Fill free to ask questions during my lectures.
In addition, I would also be happy to answer any questions after class. My office is in Room 441 BSB. My email address is [email protected] and my phone number is 792-2550.
Robert J. Boackle, Ph.D. Please be sure to study the chapter on Complement
Complement
A series of Blood Serumcomponents which existin a NON-ACTIVE state
The Primary Functions
of the Complement System
1) Quickly Neutralize anything that activates complement by permanently coating the activator
2) Enhance the Phagocytosis of that complement-coated substance
3) Directly damage that complement-coated membrane (e.g., if the activator is a susceptible microbe)
The Primary Functions
of the Complement System
Complement Components are produced Primarily by
“HEPATOCYTES”
MACROPHAGES and many different cell types also produce complement components
Fast Acting (2 min)
Potent
Tightly Controlled
Cascading/AmplifyingSequence
COMPLEMENT
1) FRAGMENTATION
2) CONFORMATIONAL CHANGE
3) ACTIVATION
Activation by Immune Complexes
The Classical Pathway(Most Powerful Pathway)
C1
C4 C2 C3
C5
C6
C7
C8
C9Membrane damage
(Amplification Loop -Alternative Pathway)C3b, Factor B, Factor D
MembraneAttackComplex
C4b, C3b, iC3b, C3dg, C3d Immune Adherence Enhanced Phagocytosis
C3a, C5a Anaphylotoxins Chemotactic Factors
(
)
Membrane Damage & Potential for Cell Lysis
Classical Pathway Activation by Immune Complexes
Lectin Pathwayweakest pathway
MBL MASP1 + MASP2
C1
C4 C2 C3
C5
C6
C7
C8
C9
C4 C2
C
3
C5
C6
C7
C8
C9
C4 C2 C3
C5 C6
C7 C8
C9
Cascading - Amplifying SequenceAt many steps, especially at C1 and C3
C
3
C5
C
6
C7
C
8
C9
C3 C
5 C6 C
7 C8 C
9
(Amplification Loop)
Control at these two steps is important.
C1q Stem region
C1q Globular Heads
C1q is a subcomponent of the first complement component C1
(Native C1) The first Complement Component, C1 = Macromolecular C1qr2s2
C1r2 and C1s2C1q
C1
C1q Globular Headsbind to the exposed Fc region of IgM, IgG3 or IgG1 Immune Complexes, but not to IgA nor IgG4
C1 Structure, after C1 activation
C1r
= Catalytic Domain
Activated C1s
Activated C1s
CH2 CH3
CH2 CH3
Movement within the
HingeRegion
IgG3 or IgG1
Movement within the
HingeRegion
CH2 CH3
CH2 CH3
IgG3 or IgG1ANTIBODIES
C1q globular heads bind CH2 gamma, but only if the Fab regions have
bound antigen and moved
so as to expose the CH2 gamma
Foreign(Antigenic)
cell/viral surface
Antigenic determinant
Antigenic determinant
C
H2
C
H3
C
H2
CH
3 C1
IgG3 or IgG1
Antigenic Surface
At least two or more IgG
antibodies are required but only one IgM (5 Fc regions)
At least two
adjacent IgG
C
H2
C
H3
C
H2
CH
3
IgG3 or IgG1
Antigenic Surface
At least two
adjacent IgG
C1q conformational changes are induced after binding to adjacent IgG
antibodies on the antigenic surface;Followed by C1r2 then C1s2 activation
IgG3 or IgG1
Antigenic Surface
At least two adjacently deposited IgG antibodies are needed to bind C1, but the more deposited IgG on the antigenic surface the better the interaction with C1 becomes. This requirement for sufficiently deposited levels of antibody insures that complement is not inadvertently activated.
However, pathogens that either mutate their immunogenic epitopes or slough their epitopes defeat or circumvent the proper action of the classical complement pathway.
FOREIGN SURFACE
Active Host Enzymes now on the Antigen
CH2 Flexibility of C1q
C1r2-C1s2
C1q
FOREIGN SURFACE
C1SC1S2
C4
Activated
FOREIGN SURFACE
C1SC1S2
C4b
Short-lived Active Binding Site
FOREIGN SURFACE
C1SC1S2
C4b
Covalent BindingVirus Neutralization
C4b
C4 Binding Protein
C4b that did not bind to the antigen is quickly degraded
If C4b Remains Unbound
FACTOR I(protease)
Note: Bordetella pertussis accumulates serum C4 Binding Protein, resulting in Factor I-mediated inactivation of bound C4b on its surface
Antigenic Surface
C1s
C4bC1q
C1r2
C4a2
C4b C4bC4b
C4C4
Antigenic Surface
C1q
C1r2 2
C4b
C2 C2
C2bC2a
C2a
C4b
C2a
C4b
C2a
C2b
C1s
C4b2a is a C3 Convertase
enzyme complex
C2a
C4b
ANTIGEN
C4b2a is a C3 convertase enzyme
C1s is no longer needed.C1 Inhibitor travels between the now loosened C1q stems andIrreversibly binds andinactivates C1r and C1s
C2
C4b
Native C3
GLY- CYS - GLY- GLU - GLU -THR
S C O
C4b
ANTIGEN
GLY- CYS - GLY- GLU - GLU -THR
H
ANTIGEN
C3b
C OS
Both C4b and C3b are covalently boundto the antigen via the short-lived active binding site.
C2a
C3b may alsoattach
covalently toC4b on C4b2a
C3b
C3b
As soon as C4b and C3b areCovalently boundto the antigenic surface
C3a
C3a
C3a does not bind to antigen, it is released
Antigenic SurfacewV wV
C4b
Regions on C4b and C3b become “Exposed.”Host Phagocytes attach to these regions on the deposited complement
Antigenic Surface
C4b
C2a
C3b
wC4b
C2a
C3b
w w
C3b
w
Immune Adherence & Enhanced Phagocytosis
of the complement-coated antigen
PMN or any Phagocyte
One of the “major” functions of complement is to enhance Phagocytosis
Each activated complement component
has at least one inhibitoror inhibitory mechanism
Complement Regulation
The powerful fast-acting complement system must be
controlled at each step or disease ensues due to non-productive
depletion of complement.
iC3b
C4b
C2a
C3b
C4b
C2a
C3b
Antigenic Surface
C3c
C3c
C3d
C3b
Release of C1
C1 Inhibitor
Inactivation and removal of C1 occurs as C4b and C3b deposit on the Fab (CH1) or on the antigenic determinants and disrupt the immune complexes, which in turn cause a loosening of the C1qr2s2 complex and allows entrance of C1-Inhibitor.
C3b
Dissolution of Immune Complexes
Release of Ab
C1-Inhibitor binds and then removes the inactivated C1r and C1s. However, when low levels of deposited IgG are present, the entire C1qr2s2 complex is removed by the action of C1-Inhibitor. Trace amounts of heparin bind to C1q and facilitate the C1-inhibitor mediated inactivation of activated C1r2 and C1s2 and the removal of C1qr2s2 thereby allowing a more efficient maintenance/usage of the (residual) complement components.
Deficiency of Early Complement Components (C1r, C1s, C4 or C2)Insufficient complement activation on the antigen-No loosening of the Immune Complexes
SLE and/or Glomerulonephritis- Inability to clear immune complexes faster than they are forming
Possible consequences
C1q
C1r C1s
Activated C1, when not bound to immune complexes is rapidly inhibited by
C1- Inhibitor
Complement Regulation
Prevents Auto-activation of Native C1 by Activated C1
C1q
C1r C1s
Activated C1, when not bound to immune complexes is rapidly inhibited by
C1- Inhibitor
Complement Regulation
In the absence of sufficient control by C1-Inhibitor, activated C1r in one (released) activated C1 will activate C1r in other Native C1 (C1 auto-activation) resulting in escalating C1 auto-activation, C4 and C2 consumption and continual depletion of C1-Inhibitor.
C1 Inhibitor DeficiencyGenetic: 1. Silent Gene - 25% of Normal C1 INH2. Dysfunctional Gene Product In Both Cases C1 Inhibitor Function is down and C4 levels are lower than normal
Acquired: Lymphoproliferative Disorders
Angioneurotic edema
(Angioedema)NO Control over unbound
activated C1 resulting in total depletion of C4 and C2 and most importantly temporary depletion of C1-inhibitor, resulting in lowered control
over Kallikrein and subsequent Bradykinin formation.
Plasma Prekallikrein circulates complexed with high molecular weight kininogen. (Kallikrein activity is controlled by
C1 INHIBITOR), Uncontrolled Activated Kallikrein cleaves kininogen to release Bradykinin.
In Breast Cancer
•Elevated Ca++ levels are often observed that may slightly disrupt C1qr2s2, making it more difficult to activate complement on an antibody-coated cancer cell surface
•Poor specific antibody responses (to cancer cells)
•Elevated levels of complement inhibitory molecules on the surface of the cancer cells
•Small levels of complement deposition actually cause surviving cancer cells to become more resistant to apoptosis.
Complement and Breast Cancer
COMPLEMENT (C3b & C4b)
Neutralizes Endotoxin
Neutralizes VirusesVirus no longer binds to the target host cell properly
Changes the nature of the substance..no longer endotoxin
C2a
C4b
C3b
ANTIGEN
C5
C5a
C5a is a “very strong Chemotatic Factor”
C3b
C5 joins the complex after one or two C3b molecules bind.
C5aC5b
C3b
C5b
C5a
C3a
PMN
PMN
TISSUEINFECTION
Concentration Gradient of C5a and C3a
C3a & C5a
PMN
PMNC5a
C3a
PMN
Complement Coated Antigen
UP-REGULATION -- Higher Expressionof Complement Receptors on PMN
PMN
C3a & C5a
TISSUE INFECTION
Infected Tissue
ARTHUSREACTION
PMN
PMN
Complement Coated Antigen
C3a and C5a bind to Mast Cells and Basophiles
Mast CellThen Mast Cells and Basophiles release
Histamine
and Heparin
C3a
C5a
Mast Cell
Histamine Release
C3a
C5a
Histamine
Edema
C5-9
Classical Pathway C1
C4 C2 C3
C5
C6
C7
C8
C9
“Membrane damage”
Lectin Pathway
Alternative Pathway(Amplification Loop)
MembraneAttackComplex(MAC)
Polymerized C9
C7
C8
C5bC6
C5bC6
C7
Cell Membrane
Transmembrane Channel
C8 enters the membrane, then the polymerized C9 causes the lesion.Then the cell swells.
Membrane Attack Complex, C5-C9
MAC cell surface lesions
MAC cell surface lesions
Bacteria(Certain E.
coli)
SHED PILIeliminate MAC
Protective Mechanisms on Host Cell Membranes
Host Cells Must Protect Themselves from Inadvertent Complement Attack
Complement Receptor 1CR1 (CD35)
Decay Accelerating Factor DAF (CD55)
Membrane Cofactor ProteinMCP (CD46)
Protectin (CD59)
Protective Mechanisms on Host Cell Membranes
Over-expressed on host cells that are located in inflamed areas or on Cancer Cells
Xenograph Organ Transplant Research Goal: Genetically program foreign cells (animal organs) to express these “human” complement regulatory substances and defeat destruction by Ab and the Classical Complement Pathway
Protective Mechanisms on Host Cell Membranes
How do these normal cell surface proteins protect host cells in areas of complement-mediated
inflammation from inadvertent complement attack?As an example, we will discuss the mechanism for
Membrane Cofactor ProteinMCP (CD46) and Complement Receptor One (CR1)
(the textbook chapter provides more complete information)
HOST CELL
Factor I(a serum protease)
Inactivated iC3b Complement Cascade is stopped
MCP
If C3b inadvertently deposits on a host cell. Then, CR1 and or MCP as a part of that host cell membrane will serve as cofactors for serum Factor I
MCP MCP
Alternative Complement Pathwayin the absence of Classical Pathway activation
1) Represents a first line of defense before substantial levels of Ab are produced
2) Is always ready to be activated by a susceptible surface
Always remember that the Amplification Loop of the classical pathway has the same molecular steps as the Alternative Pathway
The Alternative Pathway
Non - specific (does not require antibody)
Less Efficient (requires more of the activator)
Mg++ Dependent
By definition does not require C1, C4 or C2
although the Classical Pathway will activate it!
C1
C4 C2 C3
C5
C6
C7
C8
C9 Membrane damage
C3a, C5aAnaphylotoxinsChemotactic Factors
C4b, C3b, iC3b, C3dg, C3dImmune AdherenceEnhanced Phagocytosis
Alternative PathwayC3b, Factor B and Factor D
“Must start with a Bound C3bThat has not been inactivated”
C3b
C3 Amplification Loop or
Thus, serum FACTOR B will bind to any Deposited C3b
that has not been Inactivated
C3bFactor BPRO-ENZYMEnow ready to become activated
Activator / Antigen
C3bFactor Bb
Activator / Antigen
Factor D
activated
C3bBb activates more C3“Amplification of C3b deposition”
C3bFactor Bb(Activated)
Native C3
Antigen
Activated Factor B when bound todeposited C3b will now activate more native C3
C3bFactor BbEnzyme
NATIVE C3
C3aAmplification Loop
Antigen
Note that Factor Bb has enzymatic functions almost like C2a
C3b
Factor Bb
C3b
C3
ANTIGEN
More C3b is Deposited
C3 Amplification LoopC3bBb enzyme
C3b
Factor BC3b
C3
ANTIGEN
FACTOR B
More Factor B bindsso more C3 can be activated
Factor C3bBb activates C3 and C5
C3b
FACTOR B
( similar to C2 )
MO
RE
Activator / Antigen
MO
RE
C3b
Factor BAdheres to deposited C3b, if C3b is bound to an antigen.
If the surface to which C3b binds has no built-in protection against complement (like host cells do)
e.g. no CR1, MCP or DAF
that surface will activate the Alternative Pathway(the C3b-Amplification Loop).
This includes most microbes and artificial substances,for example “Cellophane filters used in leukophoresis”
C3b
FACTOR H
In addition, Factor H is the primary Inhibitor of
unbound C3b
When C3b fails to bind to antigen, Factor H “quickly” binds to the C3b, this attracts the Factor I protease, then C3b is rapidly inactivated by Factor I to form iC3b FACTOR I
serum protease i
Pathogens have mechanisms to circumvent the immune system. Streptococcus pyogenes
Neisseria gonorrhoeae
Candida albicansEach of these pathogens express molecules that attract and accumulate host serum Factor H onto its microbial surface that
promote a rapid serum Factor I mediated cleavage of any
deposited C3b to form iC3b. [Inactivated C3b (iC3b) can not participate in the amplification loop.] As a result, less C3b is deposited on these organisms.
If C3b becomes inadvertently bound to a host cellor becomes bound to an antibody-coated cancer cell
Host Cell Surface Co-Factor
either CR1 or MCP (CD46)
C3b
Factor I
Host Cell has evaded the attack
no amplification
loop
i
PMNs can endocytose small amounts of C3b or
iC3b or C3d that inadvertently deposit on
their surfaces
Complement Receptor 1CR1 (CD35)
Decay Accelerating Factor DAF (CD55)
Membrane Cofactor ProteinMCP (CD46)
CD46 just happens to be a receptor for measles virus (MV) MV infection may cause host immune suppression, secondary to signaling
events through CD46 on dendritic cells and macrophages.
Protectin (CD59)
.
Host Cell Protective Mechanisms
Decay Accelerating Factor DAF (CD55)
Blocks the interaction of C4b and C3b with the subsequent complement
components
Protectin (CD59)
Blocks the function of C8 and C9
Two additional the host cell surface Protective Mechanisms
phosphatidylinositol “anchored” to the host cell
Paroxysmal Nocturnal Hemoglobinuria (PNH) An acquired disorder of phosphatidylinositol "anchors" on selected hemopoietic stem cell lines and their particular erythrocyte progeny. The patients develop anemia associated with the intermittent passage of dark urine. The hemoglobinuria is due to an increased susceptibility of the abnormal population of innocent bystander erythrocytes to complement-mediated lysis, when complement is activated. The deficiency of the phosphatidylinositol anchoring system is reflected by deficiencies of DAF (CD55) and Protectin (CD59). Type I PNH red cells have normal levels or slightly lowered levels of these two proteins and usually show normal resistance to complement-mediated hemolysis. Type II PNH erythrocyte populations lack DAF and have intermediate sensitivity to hemolysis. Type III PNH erythrocyte populations lack both proteins and are very sensitive to hemolysis.
SS
S S
chain C3 chain
C3d C3g
Tissue protease or plasmin
S S
C3dgC3c
Factor IC3c goes into the fluid phase
SS
S S iC3b
Factor I with co-factor H or CR1 or MCP
SS
S S C3b
C3 ConvertaseC4bC2a or C3bBb
C3a
SS
Covalently bound to the antigen
The speed of the C3b
breakdown (catabolism) depends on the nature
of the substance
onto which C3b
covalently binds
Phagocytes
have receptors for all of the covalently-bound
C3 fragments
COMPLEMENT RECEPTOR
EXPRESSED ON
BINDINGSPECIFICITY
ERYTHROCYTES
PMN
MONOCYTES /
MACROPHAGESCR1universal
GLOMERULARPODOCYTES
C3b
C4b
CR4PMN
MONOCYTES /
MACROPHAGES
CR3PMN
MONOCYTES /
MACROPHAGES
iC3b
C3dC3dg
COMPLEMENT RECEPTOR
EXPRESSED ON
BINDINGSPECIFICITY
CR2 B cells iC3b C3dg C3d
(EB virusreceptor)
Complement deposition (C3b and C3d) on Antigens amplifies the stimulation of B Cells (that have CR2 and CR1, in
addition to their specific Ab-receptors for the antigen) and enhances the subsequent Antibody production by a 1000 fold.
Dendritic Cells
Role of
Complement Receptor 1
(CR1)
on
Erythrocytes
Complement Coated Immune Complexes are picked-up from the serum by Erythrocytes and Delivered to Phagocytes.
Complement CoatedANTIGEN
ANTIBODY
COMPLEX
Erythrocyte
CR1
CR1
CR1
CR1
CR1
Complement Coated Immune Complexes are picked up from the serum by Erythrocytes and Delivered to Phagocytes.
CR1
CR1
CR1
CR3
CR3
CR3
CR3
CR4
CR4
CR4
CR4
Phagocyte
Complement CoatedANTIGEN
ANTIBODY
COMPLEX
Erythrocyte
CR1
CR1
CR1
CR1
CR1
RELEASE OF COMPLEMENT COATEDIMMUNE COMPLEXES TO PHAGOCYTE
CR1 interaction weakens
Erythrocyte
CR1
CR1
CR1
CR1
CR1
CR1
CR1
CR1
CR3
CR3
CR3
CR3
CR4
CR4
CR4
CR4
Phagocyte
ANTIGEN
ANTIBODY
COMPLEX
Complement Coated
RELEASE OF COMPLEMENT COATEDIMMUNE COMPLEXES TO PHAGOCYTE
CR1 interaction weakens
Erythrocyte
CR1
CR1
CR1
CR1
CR1
CR1
CR1
CR1
CR3
CR3
CR3
CR3
CR4
CR4
CR4
CR4
Phagocyte
ANTIGEN
ANTIBODY
COMPLEX
Complement Coated
Deficiency of 1) Early Complement Components (C1r, C1s, C4 or C2)
2) CR1 (on erythrocytes)
SLE and/or Glomerulonephritis- Inability to clear immune complexes
Possible consequences
HIV-1
In addition to remaining dormant inside the DNA of host cells (such as CD4 positive cells), and continually changing its immunodominant epitopes, HIV-1 virions (when released into the serum from an infected host cells) are protected from the complement system in several ways:
HIV-11) Acquires DAF (CD55) upon leaving the
host cell
2)Attracts Factor H from serum
3)Sheds many of its trimeric gp160 spikes
In addition to continually changing its immunodominant epitopes, these above properties allow a percentage of HIV-1 particles to escape neutralization by antibody and complement. A low level, non-neutralizing C3b-iC3b-C3d deposition may actually help HIV-1 to be more persistent in lymph nodes.
HIV-1 Virion Structure
• ~ 100 nm diameter
• 20 faced icosahedron with 12 vertices
• 3 envelope spikes on each face and one at each vertex = 72 spikes
– Based on underlying structure
•Actual mature HIV-1 virion has only 7-15 spikes due to shedding limits IgG aggregation
humanvaccine.duke.edu, 1/12/06
Y
Y
PANCREATITIS
CARDIAC INFARCTION
ORGAN FAILURE
SEVERE BURNS
Sudden Release of Proteases
C5a Induced Granulocyte Aggregation
Blockage of Capillaries by Granulocytes
+Superoxide Stimulation
Massive Complement Activation
SHOCK
RESPIRATORY DISTRESS SYNDROME
EXTENDED DAMAGE IN CARDIAC INFARCTION
RETINAL DAMAGE - TEMPORARY BLINDNESS
C5a Induced Granulocyte Aggregation
ACTIVATION OF CLASSICAL ANDALTERNATIVE PATHWAYS BY
BIOMATERIALS
Hemodialysis (Cellophane Filters)
Oxygenators (Silicone Polymers)
Filtration Leukopheresis (Nylon Fibers)
Contrast Media (X-Ray Examination)No CR1, no MBP, so No Way
To make C3b inactive
The Lectin Complement Pathway
Very Similar to C1qr2s2 and C1-Mediated Activation
Like the Alternative Pathway, this is another primitive back-up system to activate complement (and save your life), before substantial levels of specific IgG antibodies are produced.
MBL and Ficolins are carbohydrate binding Lectins in human serum that look like C1q, all three have a umbrella-like appearance.
However, rather than C1q, the Lectin Complement Pathway begins with the
binding of host serum glycoproteins termed:
1) Mannan Binding Lectin (MBL) or by
2) Ficolins (FCNs)
Normally, both of these lectins are at a relatively low concentrations in human serum.
C1qr2s2
MBL-MASP1, MASP2 & MASP3
FCN-MASP1, MASP2 & MASP3
Pro-enzymes
Lectin Pathway (ancient & weakest Pathway)
1) Human Mannan Binding Lectin (MBL) or2) Human Ficolins (FCNs) These are Human Serum Lectins, which remainassociated with serum serine proteases termed MASPs (rather than C1r and C1s). Upon binding to microbial structures, such as
Mannan, Lipoteichoic Acid, or Peptioglycan, the MASP (pro-enzymes) proteases within the Lectin-MASP complexes become activated and in turn activate C4, C2 and C3. Mannan is a capsular substance of pathogenic fungi and yeasts (e.g., Cryptococcus neoformans and Candida albicans).
C4 C2 C3
C5
C6
C7
C8
C9
C1qr2s2MBL-MASP1, MASP2 & MASP3
FCN-MASP1, MASP2 & MASP3
All three “lectins” remain associated with their respective serum pro-enzymes. After the lectins bind to their respective targeted substance, their associated activated enzymes are capable of activating early complement components.